II. Indications
- Peptic Ulcer Disease
- Gastroesophageal Reflux
- Erosive Esophagitis
- Zollinger-Ellison Syndrome
III. Contraindications
- Hypersensitivity to Proton Pump Inhibitors
- Use with caution in severe liver disease
- Limit to maximum dose of 20 mg/day (except in Zollinger Ellison Syndrome)
IV. Medications
- Esomeprazole Magnesium (Nexium)
- Standard, original Esomeprazole and generic in 2014
- Esomeprazole Delayed Release OTC 20 mg
- Esmeprazole Delayed Release 40 mg and oral suspension are trade name and prescription only
- Esomeprazole Strontium
- Dose 49.3 mg orally daily is equivalent to Esomeprazole Magnesium (Nexium) 40 mg
- Created as a patent extender in 2014 by changing the Esomeprazole salt from Magnesium to strontium
- Do not use in children due to possible bone adverse effects with Strontium
- Very expensive ($150/month in 2014) and no advantage over soon to be generic Esomeprazole Magnesium (Nexium)
- (2014) Presc Lett 21(2): 8
V. Dosing: Adults
- See Helicobacter Pylori Treatment
- Background
- Take at least one hour before meals
- Capsule contents may be sprinkle on apple sauce (and may be given via NG tube)
- Erosive Esophagitis
- Take 40 mg orally daily for 4 to 8 weeks, and then 20 mg orally daily for up to 6 months
-
Gastroesophageal Reflux
- Take 20 mg orally daily for up to 4 weeks
- Zollinger-Ellison Syndrome
- Take 40 mg orally twice daily
-
Gastrointestinal Prophylaxis of Peptic Ulcer Disease
- Take 20 to 40 mg orally daily for up to 6 months
VI. Dosing: Children
- Indicated in Pediatric Gastroesophageal Reflux
- Weight 3 to 5 kg
- Give 2.5 mg orally daily for up to 6 weeks
- Weight 5 to 7.5 kg
- Give 5 mg orally daily for up to 6 weeks
- Weight 7.5 to 20 kg
- Give 10 mg orally daily for up to 6 weeks
- Weight >20 kg and age <11 years
- Give 20 mg orally daily for up to 8 weeks
- Age <12 to 17 years
- Take 20 to 40 mg orally daily for up to 8 weeks
VII. Pharmacokinetics
VIII. Mechanism
IX. Adverse Effects:
X. Precautions
XI. Safety
- Pregnancy Category B
- Unknown safety in Lactation
XII. Efficacy
XIII. Drug Interactions
- See Proton Pump Inhibitor
- Methotrexate (high dose)
-
Voriconazole
- Doubles the serum levels of Esomeprazole
XIV. Resources
- Esmeprazole Magnesium delayed release (DailyMed)
XV. References
Images: Related links to external sites (from Bing)
Related Studies
esomeprazole (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ESOMEPRAZOLE DR 10 MG PACKET | Generic | $7.17 each |
ESOMEPRAZOLE DR 20 MG PACKET | Generic | $6.97 each |
ESOMEPRAZOLE DR 40 MG PACKET | Generic | $6.93 each |
ESOMEPRAZOLE MAG DR 20 MG CAP | Generic | $0.16 each |
ESOMEPRAZOLE MAG DR 40 MG CAP | Generic | $0.17 each |
nexium (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NEXIUM DR 10 MG PACKET | Generic | $7.17 each |
NEXIUM DR 2.5 MG PACKET | $9.20 each | |
NEXIUM DR 20 MG PACKET | Generic | $7.28 each |
NEXIUM DR 40 MG CAPSULE | Generic | $0.17 each |
NEXIUM DR 40 MG PACKET | Generic | $6.74 each |
NEXIUM DR 5 MG PACKET | $9.19 each |
Ontology: Esomeprazole (C0937846)
Definition (MSH) | The S-isomer of omeprazole. |
Definition (MSHCZE) | S-izomer omeprazolu, neracemická forma inhibitoru protonové pumpy. |
Definition (NCI_NCI-GLOSS) | A drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. |
Definition (NCI) | The S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D064098 |
SnomedCT | 317331009, 396047003 |
LNC | LP171396-7 |
English | esomeprazole (medication), esomeprazole, Esomeprazole, Esomeprazole [Chemical/Ingredient], ESOMEPRAZOLE, Esomeprazole (product), Esomeprazole (substance) |
Czech | esomeprazol |
French | Ésoméprazole |
German | Esomeprazol |
Italian | Esomeprazolo |
Russian | ЭЗОМЕПРАЗОЛ, EZOMEPRAZOL |
Spanish | Not Translated[Esomeprazole], esomeprazol (producto), esomeprazol (sustancia), esomeprazol |
Portuguese | Not Translated[Esomeprazole] |
Ontology: Nexium (C0939400)
Definition (CHV) | brand name of a drug used to treat heartburn and acid reflux |
Definition (CHV) | brand name of a drug used to treat heartburn and acid reflux |
Definition (MSH) | Esomeprazole magnesium trade name. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D064098 |
English | nexium [brand name], nexium, NexIUM, Nexium, AstraZeneca Brand of Esomeprazole Magnesium |
German | Nexium |
Spanish | Nexium |
Portuguese | Nexium |